Somatrem

Parenteral
Growth hormone deficiency

Active neoplasms or intracranial lesions; closed epiphyses. Pregnancy. Proliferative or preproliferative diabetic retinopathy. Patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment.

DM (adjustment of antidiabetic therapy may be necessary); acute catabolic states (severe burns or critically ill). Lactation. Discontinue treatment if there is evidence of tumour growth. Monitoring during therapy is recommended in patients with scoliosis due to risk of progression of scoliosis that can occur with rapid growth. Hypothyroidism may develop during therapy causing suboptimal response.

Redness, itching, lumps or lipoatrophy at inj site. Headache, muscle and joint pain, benign intracranial hypertension. May increase risk of ear disorders in patients with Turner's syndrome.

Parenteral: C

Growth-promoting effect may be inhibited by corticosteroids.

Description: Somatrem is an analogue of somatropin containing an additional (methionyl) amino acid residue. It is commonly used in children with open epiphyses for the treatment of short stature due to deficiency of growth hormone. May also be used in adults with confirmed growth hormone deficiency or management of wasting or cachexia associated with AIDS.

Trophic Hormones & Related Synthetic Drugs